How has been the historical performance of Concord Drugs?

Answer:The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four fiscal years.

Breakdown:
Concord Drugs reported net sales of 45.25 Cr for the year ending March 2025, a slight increase from 44.93 Cr in March 2024, but a notable decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025 compared to 44.93 Cr in the previous year, while it was significantly higher in earlier years. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, reflecting a gradual decrease from 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, which is a slight increase from 4.05 Cr in March 2024 but down from 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax also declined to 0.69 Cr in March 2025 from 1.25 Cr in March 2023 and 2.25 Cr in March 2022. Consequently, profit after tax fell to 0.34 Cr in March 2025, down from 0.99 Cr in March 2023 and 1.59 Cr in March 2022. The company's total assets increased to 65.14 Cr in March 2025 from 58.81 Cr in March 2024, while total liabilities also rose to 65.14 Cr from 58.81 Cr in the same period. Cash flow from operating activities improved to 3.00 Cr in March 2025, compared to 1.00 Cr in March 2023, but the overall cash flow situation remained stagnant with no net cash inflow or outflow reported.